sponsored
PatientsVille.com Logo

PatientsVille

Efudex Medical Research Studies

Up-to-date List of Efudex Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Efudex Medical Research Studies

Rank Status Study
1 Recruiting Random P2 Study of Postoperative Interferon/Fluorouracil vs Low-dose Cisplatin/Fluorouracil for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus.
Condition: Hepatocellular Carcinoma
Interventions: Drug: Interferon Alfa、Fluorouracil;   Drug: Cisplatin、Fluorouracil
Outcome Measures: Two-year overall survival rate;   Progression free survival time;   Overall survival time;   toxicity
2 Recruiting Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer
Condition: Rectal Cancer
Interventions: Drug: Sorafenib;   Drug: 5-Fluorouracil (5-FU);   Radiation: Radiation
Outcome Measures: Maximum Tolerated Dose (MTD);   Number of Participants With Pathologic Response;   Number of Participants With Serious Adverse Events (SAEs)
3 Recruiting Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
Conditions: Recurrent Rectal Cancer;   Stage IIA Rectal Cancer;   Stage IIB Rectal Cancer;   Stage IIC Rectal Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Rectal Cancer
Interventions: Drug: trametinib;   Drug: fluorouracil;   Radiation: radiation therapy
Outcome Measures: Identify the maximally tolerated dose of Trametinib to be used in combination with 5FU and radiation in patients with rectal cancers.;   Frequency of dose-limiting toxicities, assessed according to the NCI CTCAE version 4;   Local failure rate;   Progression free survival;   Overall survival;   Pathological response rate, defined as extent of tumor in the resected specimen that is classified by tumor, lymph node, metastasis (TNM) staging of the AJCC/International Union Against Cancer (UICC);   Frequency of patients undergoing sphincter preserving surgery
4 Unknown  Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: pralatrexate;   Drug: fluorouracil;   Other: laboratory biomarker analysis;   Genetic: DNA analysis;   Other: high performance liquid chromatography;   Genetic: polymerase chain reaction;   Genetic: nucleic acid sequencing;   Other: pharmacological study;   Other: pharmacogenomic studies;   Genetic: polymorphism analysis
Outcome Measures: Recommended dose of PDX given in combination with a fixed dose of 5-FU administered as a 48-hour infusion given every other week;   Clinical response to therapy in subjects with measurable disease and time to disease progression in all subjects;   Toxicity profile of the combination of PDX and 5-FU;   Pharmacokinetics of PDX and 5-FU and correlate with clinical toxicity;   Polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and correlate with clinical toxicity
5 Recruiting Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Condition: Second Line Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Glufosfamide;   Drug: Fluorouracil
Outcome Measure: Overall Survival
6 Recruiting Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer
Condition: Rectal Cancer
Interventions: Drug: fluorouracil;   Drug: fluorouracil, oxaliplatin
Outcome Measures: 3-year disease free survival;   objective response rate,pathologic complete response rate, sphincter-saving surgery rate, biomarkers, quality of life, toxic profile, convenience
7 Recruiting A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma
Condition: Esophageal Squamous Cell Carcinoma
Interventions: Drug: Paclitaxel plus 5-fluorouracil;   Drug: Cisplatin plus 5-fluorouracil;   Radiation: Radiation therapy
Outcome Measures: 1-yr overall survivals;   2-yr overall survival;   3-yr overall survival;   Disease progression-free survival;   Local progression-free survival;   Number and grade of Participants with Adverse Events
8 Recruiting Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
Condition: Cancer
Interventions: Drug: Paclitaxel;   Drug: 5-Fluorouracil (5FU);   Drug: Carboplatin;   Drug: Leucovorin;   Drug: Irinotecan;   Drug: BMS-906024
Outcome Measures: Safety assessment based on reports of adverse events and clinical laboratory tests as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE);   Maximum observed plasma concentration (Cmax) of BMS-906024 and BMS-911557 (the active metabolite of BMS-906024), Paclitaxel, Irinotecan, SN-38 (the active metabolite of Irinotecan) and Carboplatin;   Trough observed plasma concentration (Cmin) of BMS-906024 and BMS-911557 (the active metabolite of BMS-906024), Paclitaxel, Irinotecan, SN-38 (the active metabolite of Irinotecan) and Carboplatin;   Time of maximum observed plasma concentration (Tmax) of BMS-906024 and BMS-911557 (the active metabolite of BMS-906024), Paclitaxel, Irinotecan, SN-38 (the active metabolite of Irinotecan) and Carboplatin;   Area under the concentration-time curve during a dosing interval of tau [AUC(TAU)] of BMS-906024 and BMS-911557 (the active metabolite of BMS-906024);   Area under the concentration-time curve from time 0 to the time of the last sample collected in the dosing interval [AUC(0-T)] of Paclitaxel, Irinotecan, SN-38 (the active metabolite of Irinotecan) and Carboplatin;   Steady-state infusion concentration (Css) of 5-Fluorouracil (5-FU);   Tumor response [as defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria], best overall response (BOR), duration of response, and progression free survival (PFS) will be assessed;   Gene mutation status of Notch activation markers as well as other genes of interest in relevant indications, in tumor, and gene expression levels of Notch activation markers, such as but not limited to Hes1, Deltex1, in tumor
9 Recruiting 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: Oxaliplatin;   Drug: Docetaxel;   Drug: Epirubicin;   Drug: Cisplatin;   Drug: 5-fluorouracil
Outcome Measures: median overall survival;   histopathological regression rate;   disease free survival (DFS);   correlation of pCR and DFS with survival;   Perioperative Morbidity and Mortality;   R0-Resection rate
10 Recruiting Induction Therapy-Docetaxel, Cisplatin and Fluorouracil in Untreated Advanced Squamous Cell or Undifferentiated Carcinoma of the Paranasal Sinuses
Conditions: Paranasal Sinus Neoplasms;   Squamous Cell Carcinoma
Interventions: Drug: Docetaxel;   Drug: 5-Fluorouracil;   Drug: Cisplatin
Outcome Measure: Number of Patients with Complete + Partial Response
11 Recruiting Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
Condition: Metastatic Gastric Cancer
Interventions: Drug: folinic acid+fluorouracil+oxaliplatin;   Drug: Capecitabine
Outcome Measures: progression-free survival;   PFS on capecitabine maintenance;   overall survival;   number of patients with adverse events;   tolerability;   time to treatment failure;   Quality of life
12 Recruiting Intra-operative Chemotherapy With 5-FU for Colorectal Cancer Patients Receiving Curative Resection: Efficacy and Safety
Condition: Colorectal Cancer
Interventions: Procedure: curative resection for colorectal cancer;   Drug: intra-operative 5-FU chemotherapy
Outcome Measures: disease-free survival;   safety profiles
13 Recruiting Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: panitumumab;   Drug: everolimus;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin
Outcome Measures: Maximum tolerated dose of everolimus in combination with sequential fluorouracil (5-FU) and leucovorin calcium, panitumumab, modified 5-FU, leucovorin calcium, and oxaliplatin (mFOLFOX6), and mFOLFOX6 with panitumumab;   Toxicity as assessed by CTC version 3.0 at the beginning of each treatment course;   Tumor response;   Correlation of response with S6-phosphorylation and AKT-phosphorylation in archived tumor samples
14 Recruiting Paclitaxel, Carboplatin and Cetuximab (PCC) Versus Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Cetuximab;   Drug: Docetaxel;   Drug: Cisplatin;   Drug: Fluorouracil;   Radiation: Radiotherapy (RT);   Other: Chemotherapy
Outcome Measure: Number of Patients with Progression-free survival (PFS)
15 Not yet recruiting Imiquimod, Fluorouracil, or Observation in Treating Patients With High-Grade Anal Squamous Skin Lesions Who Are HIV-Positive
Conditions: Anal Intraepithelial Neoplasia;   High-grade Squamous Intraepithelial Lesion;   HIV Infection
Interventions: Drug: imiquimod;   Drug: fluorouracil;   Other: questionnaire administration;   Other: laboratory biomarker analysis
Outcome Measures: Proportion of participants achieving complete response (Arm A and B);   Proportion of participants with spontaneous regression (Arm C);   Presence of intra-anal HSIL on cytology or histology;   Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;   Proportion of participants achieving complete response or spontaneous regression;   Number of quadrants with HSIL found on biopsies;   Proportion of patients achieving complete or partial responses;   Persistence of HPV type specific infections
16 Recruiting Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007;   Drug: Gemcitabine;   Drug: simplified LV5FU2
Outcome Measures: Progression-free survival (PFS);   Tumor Response Rate;   Duration of disease control (DDC);   Overall Survival;   Quality of life;   Number of Adverse Events
17 Recruiting Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma
Conditions: Chemoradiation;   Nasopharyngeal Carcinoma
Interventions: Drug: PF (cisplatin and 5-fluorouracil) group;   Drug: TPF (docetaxel plus cisplatin and 5-fluorouracil) group
Outcome Measures: 3-year progress free survival(PFS);   overall survival(OS);   Adverse events;   local control rate (LCR)
18 Recruiting PD-0332991, 5-FU, and Oxaliplatin for Advanced Colorectal Cancer
Condition: Colorectal Cancer
Intervention: Drug: PD-0332991, 5-FU, oxaliplatin
Outcome Measures: Recommended Phase 2 dose and schedule;   Toxicity;   Pharmacodynamics;   Response rate;   Disease control rate;   Trough level of PD-0332991 on Day 1 of Cycles 1-4
19 Not yet recruiting Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer
Conditions: Colorectal Cancer;   Metastatic Colorectal Cancer
Interventions: Drug: 5-FU;   Drug: LV;   Drug: ziv-aflibercept;   Drug: mFOLFOX6
Outcome Measures: The time to disease progression;   Measurement of disease status by continuous tumor measurement;   The frequency of adverse events;   The severity of adverse events
20 Recruiting Colorectal Cancer (CRC) Cetuximab Elderly Frail
Condition: Colorectal Cancer Metastatic
Interventions: Drug: Cetuximab;   Drug: 5-fluorouracil;   Drug: leucovorin
Outcome Measures: Progression free survival;   Overall Survival;   Response Rate;   Change in Instrumental Activities of Daily Living (IADL) score;   Change in G8 geriatric assessment screening tool;   Change in social situation;   Score of Quality of Life (EORTC-QLQ C30 and QLQ-ELD14);   Occurrence of adverse events;   Health Economy assessments;   Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by G8 instrument;   Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by Instrumental Activities of Daily Life (IADL) questionnaire;   Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by social situation questionnaire

These studies may lead to new treatments and are adding insight into Efudex etiology and treatment.

A major focus of Efudex research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Efudex